Immunome Inc.
Immunome Inc. is a U.S.-based biotechnology company developing targeted oncology therapies, with a pipeline spanning clinical and preclinical assets. Its lead focus is varegacestat for desmoid tumors, alongside antibody-drug conjugate and radioligand programs aimed at cancer indications with high unmet need.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueVaregacestat is the company's most advanced program, targeting desmoid tumors with planned NDA submission.
ADC programs include IM-1021 and multiple preclinical solid tumor candidates built on the company's target and payload platform.
IM-3050 is a FAP-targeted radioligand therapy intended for oncology use after IND clearance.
Historical revenue came from a collaboration and option agreement with AbbVie, which has now terminated.
Customers
Immunome does not yet sell approved products commercially; its current 'customers' are primarily regulators, clinical investigators, and future oncology treatment centers that will support development and eventual adoption. If approved, varegacestat would be marketed to specialized treatment centers treating desmoid tumor patients, while broader oncology programs would target hospitals and cancer centers.
Specialized centers that would prescribe varegacestat if approved, because desmoid tumors are a niche oncology indication.
Sites participating in trials and, later, using ADC or radioligand therapies for hematologic and solid tumors.
Pharma or biotech partners that may collaborate on ex-U.S. commercialization or development.
Organizations that will influence reimbursement and access for any approved oncology products.
Strategy
The company is prioritizing late-stage development and regulatory preparation for varegacestat while continuing to advance IM-1021, IM-3050, and earlier-stage ADC assets. Its strategy is to combine internal commercialization capability in the U.S. with flexible ex-U.S. partnering, using its ADC and oncology discovery platform to build a broader pipeline.
This is the nearest-term value driver and the first potential commercial product.
These programs diversify the pipeline beyond the lead asset and validate the platform.
A wider pipeline increases the chance of future clinical and partnering success.
Geography
Immunome is headquartered in the United States and expects to commercialize varegacestat first through a U.S.-focused internal organization if approved. Outside the U.S., it may retain rights in key markets such as Europe or pursue partnerships, so future revenue and operating footprint could become more international over time.
Risks
Immunome remains a development-stage biopharma company with no approved product revenue, so execution risk is concentrated in clinical, regulatory, and financing milestones. The company also faces intense oncology competition, manufacturing and supply-chain dependencies, and the possibility that its lead asset or platform programs fail to achieve approval or commercial traction.
- Clinical development failure or delayImpact: HighLikelihood: Medium
The pipeline is still in development, and setbacks in Phase 1/3 trials could postpone or eliminate future revenue.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
The company has not yet obtained NDA/BLA approval, so commercialization depends on FDA and other regulators.
Exposure: Lead asset varegacestat and future pipeline assets
- Financing and cash burnImpact: HighLikelihood: Medium
R&D and launch preparation require substantial capital before product revenue begins.
Exposure: Ongoing clinical development and commercial buildout
- Competitive pressure in oncologyImpact: MediumLikelihood: Medium
Larger pharma and biotech peers may reach market first or offer superior efficacy/safety.
Exposure - Third-party manufacturing and supply dependenceImpact: MediumLikelihood: Medium
Clinical and launch timelines depend on external manufacturing and diagnostic supply chains.
Exposure: IM-3050 radiotracer supply and future commercial supply chain
Accounting
Judgemental itemsRevenue was recognized over the performance period under the AbbVie agreement, and that source has now ended.
Impact: No further collaboration revenue will be recognized from that contract
Clinical trial, manufacturing, and preclinical spend drive the largest operating cost line.
Impact: Quarterly losses can change materially with program timing
Non-cash equity compensation is embedded in both R&D and G&A.
Impact: Affects operating loss without immediate cash outflow
Acquired development assets may be expensed immediately if they have no alternative future use.
Impact: Can create large one-time charges and distort period comparability
License and acquisition agreements may require future payments upon development or approval milestones.
Impact: Potential future liabilities and cash outflows
Similar listed companies
Publicly listed companies with a comparable business focus.
Immunic, Inc
IMUX · Pharmaceutical Preparations
IMAC Holdings, Inc.
BACK · Services-Specialty Outpatient Facilities, NEC
Imunon, Inc.
IMNN · Pharmaceutical Preparations
Immunovant, Inc.
IMVT · Biological Products, (No Diagnostic Substances)
Actinium Pharmaceuticals, Inc.
ATNM · Pharmaceutical Preparations
Iovance Biotherapeutics, Inc
IOVA · Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
Last updated: 24/09/2026